The increasing costs of labor and supplies are the top issues keeping healthcare CFOs up at night, according to a new report. Even though providers' margins are currently quite tight, the report recommended that healthcare organizations adopt data analytics software to remedy these concerns and help with important decisions like how to effectively manage their existing workforce and where to shift care delivery models.
There is no single driver of low-value care — providers, systems, and patients all play a role. But with the right tools, stakeholders can work together to re-align incentives and transform our healthcare delivery system into one that prioritizes value, eliminates waste and leads to better overall patient outcomes.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
The report found that Aimmune's AR101 and DBV's Viaskin Peanut lacked sufficient evidence to demonstrate that their benefits outweighed short-term risks. Aimmune and an allergy advocacy group criticized the report.